MA32064B1 - Nouvelles pyridinones et pyridazinones - Google Patents
Nouvelles pyridinones et pyridazinonesInfo
- Publication number
- MA32064B1 MA32064B1 MA33066A MA33066A MA32064B1 MA 32064 B1 MA32064 B1 MA 32064B1 MA 33066 A MA33066 A MA 33066A MA 33066 A MA33066 A MA 33066A MA 32064 B1 MA32064 B1 MA 32064B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- iii
- diseases associated
- pyridinones
- pyridazinones
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 150000005299 pyridinones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- IJUIPRDMWWBTTQ-UHFFFAOYSA-N 3-phenyl-1h-pyridazin-6-one Chemical class N1C(=O)C=CC(C=2C=CC=CC=2)=N1 IJUIPRDMWWBTTQ-UHFFFAOYSA-N 0.000 abstract 1
- RWFAQYWIBBVEBY-UHFFFAOYSA-N 5-phenyl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C=2C=CC=CC=2)=C1 RWFAQYWIBBVEBY-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Cette invention porte sur des dérivés de 5-phényl-1h-pyridin-2-one et de 6-phényl-2h-pyridazin-3-one selon les formules génériques i-iii : dans lesquelles les variables r, x, y1, y2, y3, y4, n et m sont définies comme décrit dans la description, les dérivés inhibant btk. Les composés décrits dans la description sont utiles pour moduler l'activité de btk et traiter des maladies associées à une activité de btk excessive. Les composés sont encore utiles pour traiter des maladies inflammatoires et auto-immunes associées à une prolifération aberrante des lymphocytes b telles que la polyarthrite rhumatoïde. L'invention porte également sur des compositions contenant des composés représentés par les formules i-iii et au moins un support, diluent ou excipient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2620408P | 2008-02-05 | 2008-02-05 | |
| US12251008P | 2008-12-15 | 2008-12-15 | |
| PCT/EP2009/050875 WO2009098144A1 (fr) | 2008-02-05 | 2009-01-27 | Nouvelles pyridinones et pyridazinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32064B1 true MA32064B1 (fr) | 2011-02-01 |
Family
ID=40413736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33066A MA32064B1 (fr) | 2008-02-05 | 2010-08-06 | Nouvelles pyridinones et pyridazinones |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2242749B1 (fr) |
| JP (1) | JP5259739B2 (fr) |
| KR (1) | KR101308803B1 (fr) |
| CN (1) | CN101932573B (fr) |
| AR (1) | AR070408A1 (fr) |
| AU (1) | AU2009211514B2 (fr) |
| BR (1) | BRPI0907915A2 (fr) |
| CA (1) | CA2710462C (fr) |
| CL (1) | CL2009000229A1 (fr) |
| CO (1) | CO6290767A2 (fr) |
| CR (1) | CR11598A (fr) |
| CY (1) | CY1114114T1 (fr) |
| DK (1) | DK2242749T3 (fr) |
| EC (1) | ECSP10010384A (fr) |
| ES (1) | ES2420846T3 (fr) |
| HR (1) | HRP20130615T1 (fr) |
| IL (1) | IL206357A (fr) |
| MA (1) | MA32064B1 (fr) |
| MX (1) | MX2010008197A (fr) |
| MY (1) | MY158411A (fr) |
| NZ (1) | NZ586916A (fr) |
| PE (1) | PE20091484A1 (fr) |
| PL (1) | PL2242749T3 (fr) |
| PT (1) | PT2242749E (fr) |
| RU (1) | RU2505538C2 (fr) |
| SI (1) | SI2242749T1 (fr) |
| TW (1) | TWI382024B (fr) |
| WO (1) | WO2009098144A1 (fr) |
| ZA (1) | ZA201005539B (fr) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20100851A1 (es) | 2008-06-24 | 2011-01-31 | Hoffmann La Roche | PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| ES2513915T3 (es) * | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| TWI557127B (zh) | 2009-09-04 | 2016-11-11 | 百健Ｍａ公司 | 布魯頓氏酪胺酸激酶抑制劑 |
| CA3034600C (fr) * | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Composes de pyridone et d'aza-pyridone et leurs procedes d'utilisation |
| EP2394998A1 (fr) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4 |
| AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| ES2590491T3 (es) | 2011-05-17 | 2016-11-22 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| KR20140052032A (ko) | 2011-08-17 | 2014-05-02 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| WO2013148603A1 (fr) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Dérivés de cinnoline en tant qu'en tant qu'inhibiteurs de la btk |
| JP6275690B2 (ja) | 2012-04-05 | 2018-02-07 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| US9499548B2 (en) * | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| CN104812746B (zh) * | 2012-11-16 | 2017-03-08 | 弗·哈夫曼-拉罗切有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| EP2925323B1 (fr) * | 2012-11-30 | 2017-05-17 | F. Hoffmann-La Roche AG | Inhibiteur de tyrosine kinase de bruton |
| EP2964627B1 (fr) * | 2013-03-05 | 2017-03-01 | F. Hoffmann-La Roche AG | Inhibiteurs de tyrosine kinase de bruton |
| CN105143215B (zh) * | 2013-03-05 | 2017-12-08 | 豪夫迈·罗氏有限公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| HK1214820A1 (zh) * | 2013-07-03 | 2016-08-05 | 豪夫迈．罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CN105793251B (zh) * | 2013-12-05 | 2018-10-12 | 豪夫迈·罗氏有限公司 | 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| WO2016050921A1 (fr) * | 2014-10-02 | 2016-04-07 | F. Hoffmann-La Roche Ag | Composés de pyrazole-carboxamide destinés à être utilisés dans le traitement de troubles médiés par la tyrosine kinase de bruton (btk) |
| US10570118B2 (en) * | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
| JP7305352B2 (ja) | 2016-03-31 | 2023-07-10 | 武田薬品工業株式会社 | イソキノリニルトリアゾロン錯体 |
| WO2018007885A1 (fr) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer. |
| CA3031443A1 (fr) | 2016-07-21 | 2018-01-25 | Biogen Ma Inc. | Succinate de derives de pyrimidinyle et formes solides connexes comme inhibiteurs de tyrosine kinase de bruton |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN109982687A (zh) | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| EP3573989A4 (fr) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | Formes cristallines de (s) -7- (1- (but-2-ynoyl) pipéridin-4-yl) -2- (4-phénoxyphényl) -4, 5, 6, 7-tétrahy dropyrazolo [1, 5-a]pyrimidine-3-carboxamide, préparation et utilisations associées |
| CN106967073A (zh) * | 2017-04-24 | 2017-07-21 | 刘双伟 | 一种治疗类风湿性关节炎的药物 |
| CN106946891B (zh) * | 2017-05-08 | 2018-07-13 | 宿州市徽腾知识产权咨询有限公司 | 一种用于治疗类风湿性关节炎的药物 |
| EP3645569A4 (fr) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | Immunothérapie pour carcinome hépatocellulaire |
| WO2019034009A1 (fr) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | Inhibiteur de btk ayant une double sélectivité améliorée |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| EP3867242A1 (fr) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| EP3924350A1 (fr) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire d'une voie ubiquitine-protéasome |
| CA3129665A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (fr) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Composes cyano-cyclobutyle pour l'inhibition de cbl-b et leurs utilisations |
| EP3981399A4 (fr) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | Comprimé solide pour voie orale comprenant un inhibiteur de tyrosine kinase de bruton et son procédé de préparation |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| EP4034141A1 (fr) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Inhibiteurs de cbl et compositions pour l'expansion de cellules immunitaires |
| WO2021091575A1 (fr) * | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Composés bifonctionnels pour la dégradation de btk par l'intermédiaire de la voie de l'ubiquitine-protéosome |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CA3160713A1 (fr) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Composes bifonctionnels pour la degradation de la btk par l'intermediaire de la voie de l'ubiquitine-proteosome |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3951395B2 (ja) * | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
| TR200102817T2 (tr) * | 1999-03-12 | 2002-05-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antiinflamatuar ajanlar olarak faydalı bileşikler |
| ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| MX2007007330A (es) * | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
| UY29301A1 (es) * | 2004-12-24 | 2006-07-31 | Astrazeneca Ab | Derivados amida |
| AU2006223409B2 (en) * | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2006124731A2 (fr) * | 2005-05-12 | 2006-11-23 | Irm Llc | Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases |
| AU2006279992A1 (en) * | 2005-08-09 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AU2006285038A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases |
| JP2009537520A (ja) * | 2006-05-15 | 2009-10-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法 |
-
2009
- 2009-01-27 ES ES09709135T patent/ES2420846T3/es active Active
- 2009-01-27 CN CN200980103857.3A patent/CN101932573B/zh not_active Expired - Fee Related
- 2009-01-27 CA CA2710462A patent/CA2710462C/fr not_active Expired - Fee Related
- 2009-01-27 BR BRPI0907915-7A patent/BRPI0907915A2/pt not_active IP Right Cessation
- 2009-01-27 WO PCT/EP2009/050875 patent/WO2009098144A1/fr not_active Ceased
- 2009-01-27 PL PL09709135T patent/PL2242749T3/pl unknown
- 2009-01-27 DK DK09709135.9T patent/DK2242749T3/da active
- 2009-01-27 KR KR1020107016014A patent/KR101308803B1/ko not_active Expired - Fee Related
- 2009-01-27 EP EP09709135.9A patent/EP2242749B1/fr not_active Not-in-force
- 2009-01-27 HR HRP20130615AT patent/HRP20130615T1/hr unknown
- 2009-01-27 MX MX2010008197A patent/MX2010008197A/es active IP Right Grant
- 2009-01-27 SI SI200930630T patent/SI2242749T1/sl unknown
- 2009-01-27 NZ NZ586916A patent/NZ586916A/en not_active IP Right Cessation
- 2009-01-27 PT PT97091359T patent/PT2242749E/pt unknown
- 2009-01-27 JP JP2010545433A patent/JP5259739B2/ja not_active Expired - Fee Related
- 2009-01-27 MY MYPI2010003693A patent/MY158411A/en unknown
- 2009-01-27 AU AU2009211514A patent/AU2009211514B2/en not_active Expired - Fee Related
- 2009-01-27 RU RU2010136665/04A patent/RU2505538C2/ru not_active IP Right Cessation
- 2009-02-03 AR ARP090100345A patent/AR070408A1/es not_active Application Discontinuation
- 2009-02-03 CL CL2009000229A patent/CL2009000229A1/es unknown
- 2009-02-03 TW TW098103399A patent/TWI382024B/zh not_active IP Right Cessation
- 2009-02-04 PE PE2009000169A patent/PE20091484A1/es not_active Application Discontinuation
-
2010
- 2010-06-14 IL IL206357A patent/IL206357A/en not_active IP Right Cessation
- 2010-07-26 CO CO10090865A patent/CO6290767A2/es active IP Right Grant
- 2010-07-27 CR CR11598A patent/CR11598A/es not_active Application Discontinuation
- 2010-08-03 ZA ZA2010/05539A patent/ZA201005539B/en unknown
- 2010-08-05 EC EC2010010384A patent/ECSP10010384A/es unknown
- 2010-08-06 MA MA33066A patent/MA32064B1/fr unknown
-
2013
- 2013-07-08 CY CY20131100576T patent/CY1114114T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32487B1 (fr) | Nouvelles pyridine-2-ones et pyridazine-3-ones substituees | |
| MA34465B1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MA35419B1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA32655B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
| MA29140B1 (fr) | Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10 | |
| MX2010008197A (es) | Nuevas piridinonas y piridazinonas. | |
| TNSN06369A1 (fr) | Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3 | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| MA33209B1 (fr) | Inhibiteurs de la replication du virus de l'hepatite c | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| MA31763B1 (fr) | Inhibiteurs de kinase de type polo | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| TNSN07248A1 (fr) | Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases | |
| TNSN08359A1 (fr) | Derives d'amines | |
| EA017914B8 (ru) | 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
| MXPA06014721A (es) | Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico. | |
| TNSN06358A1 (fr) | Methyl-aryl-ou-heteroaryl-amides substitues | |
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| MA28269A1 (fr) | Arylpyrazoles substitués servant d'agents parasiticides | |
| MA31766B1 (fr) | Composés organiques | |
| MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
| TW200633982A (en) | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| MA29839B1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques |